The United Kingdom and the United States have signed a significant bilateral deal that will preserve zero tariffs on British drug exports going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to increase expenditure on medicines through the National Health Service (NHS). This commitment guarantees that duties on these crucial products will remain at nothing for a timeframe of 36 months.
This deal is in response to recent statements to hike duties on branded drug imports, with figures mentioned as high as double the cost.
"This deal with the UK reinforces the worldwide climate for innovative medicines and introduces long-overdue fairness to transatlantic pharmaceutical trade," a statement noted.
Economic Importance
Medicines constitute one of the UK's largest goods shipped to the United States, which is easily the biggest destination for major companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months leading up to the third quarter, the UK exported drugs worth billions to the US. This amount accounted for a significant portion of British export trade in that period.
"This agreement safeguards employment, increases investment and paves the way for the UK to emerge as a global hub for life sciences," a government official commented.
Key NHS Changes
The pact includes several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a target to raise total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. Previously, refunds were more than twenty percent.
Industry Background
The deal follows a long-running row between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
This friction were heightened by claims that American customers were paying a premium for the equivalent treatments than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar investments have been directed toward American operations.
A senior figure stated that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a share of its total funding over the last ten years.
